Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
2019 ◽
Vol 62
(17)
◽
pp. 7643-7655
◽
Keyword(s):
2013 ◽
Keyword(s):
2015 ◽
Vol 25
(2)
◽
pp. 367-371
◽
2014 ◽
Vol 58
(1)
◽
pp. 512-516
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 256.1-256
Keyword(s):
2015 ◽
Vol 291
(6)
◽
pp. 3043-3052
◽
Keyword(s):